Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection

Straub, T. J., Lombardo, M.-J., Bryant, J. A., Diao, L., Lodise, T. P., Freedberg, D. E., Wortman, J. R., Litcofsky, K. D., Hasson, B. R., McGovern, B. H., Ford, C. B., & Henn, M. R. (2023). Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection. Clinical Infectious Diseases, 78(4), 833–841. https://doi.org/10.1093/cid/ciad636
Authors:
Timothy J Straub
Mary-Jane Lombardo
Jessica A Bryant
Liyang Diao
Thomas P Lodise
Daniel E Freedberg
Jennifer R Wortman
Kevin D Litcofsky
Brooke R Hasson
Barbara H McGovern
Christopher B Ford
Matthew R Henn
Affiliated Authors:
Daniel E Freedberg
Columbia Affiliation:
Subjects:
Clostridioides difficile (MeSH)
Microbiota (MeSH)
Clostridium Infections (MeSH)
Author Keywords:
antimicrobial resistance
clostridioides difficile infection
microbiome therapeutics
ser-109
vowst
elink
Publication Type:
Article
Unique ID:
10.1093/cid/ciad636
PMID:
37823484
DOI:
10.1093/cid/ciad636
Journal:
Clinical Infectious Diseases
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: